Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 89 of 120 for:    ZOLPIDEM AND AIDS

Improving Sleep Quality in Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03307005
Recruitment Status : Completed
First Posted : October 11, 2017
Results First Posted : February 10, 2020
Last Update Posted : February 11, 2020
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
Poor sleep quality is common in patients with heart failure. The limited available evidence intimates that improving sleep quality in patients with heart failure may improve morbidity and quality of life in this patient population. However, there is a paucity of evidence assessing the use of effective pharmacologic therapies in heart failure. The nonbenzodiazepine, GABA receptor agonist, zolpidem, has been found to have considerable benefits over traditional benzodiazepines as a soporific medication. The investigators hypothesize that zolpidem will safely improve sleep quality in patients with heart failure.

Condition or disease Intervention/treatment Phase
Sleep Disturbance Heart Failure Drug: Zolpidem Tartrate Drug: Placebo oral capsule Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Single-site, randomized, parallel, placebo controlled, double blind study
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Improving Sleep Quality in Heart Failure
Actual Study Start Date : November 1, 2017
Actual Primary Completion Date : January 25, 2019
Actual Study Completion Date : January 25, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: Intervention Drug: Zolpidem Tartrate
Zolpidem tartrate 5 mg capsule one per night taken for 7 nights

Placebo Comparator: Control Drug: Placebo oral capsule
Placebo capsule one per night taken for 7 nights

Primary Outcome Measures :
  1. Sleep Latency [ Time Frame: 1 week ]
    Mean change in sleep latency on second sleep study minus sleep latency on the first sleep study. Lower values suggest faster sleep onset. Sleep latency is measured in minutes.

  2. Total Sleep Time [ Time Frame: 1 week ]
    Mean change in total sleep time on second sleep study minus total sleep time on first sleep study. Higher values suggest more total sleep time. Total sleep time is measured in minutes.

  3. Sleep Efficiency [ Time Frame: 1 week ]
    Mean change in sleep efficiency on second sleep study minus sleep efficiency on the first sleep study. Higher values suggest more efficient sleep. Sleep efficiency is described as a percentage.

Other Outcome Measures:
  1. Insomnia Severity Index [ Time Frame: 1 week ]
    a questionnaire that assesses insomnia severity with a range of score from 0-28. Scores >=15 are signify the presence of insomnia

  2. Kansas City Cardiomyopathy Questionnaire [ Time Frame: 1 week ]
    a validated, disease-specific quality of life measure for patients with heart failure. Raw scores vary from 22-133. Lower scores signify worst heart failure-related quality of life.

  3. Epworth Sleepiness Scale [ Time Frame: 1 week ]
    a validated questionnaire that assesses chronic subjective sleepiness. The scale ranges from 0-24 with higher values signifying more sleepiness. A binary cutpoint of 11 or higher is considered significant sleepiness.

  4. Pittsburgh Sleep Quality Index [ Time Frame: 1 week ]
    a self report questionnaire that assess sleep quality. The scale ranges from 0-21. Scores higher than 5 indicate poor sleep quality

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 21-79 years old
  • HFrEF, EF ≤ 45% (by echocardiography)
  • NYHA functional class I to III
  • Able to give written consent
  • On goal-directed medical therapy for HF, with stable dosing of HF medications for 2 weeks prior to enrollment
  • No hospitalizations for HF within the past month
  • Positive response to experiencing any of the following sleep-related symptoms at least once a week:
  • Difficulty falling asleep
  • Waking up during the night and having difficulty getting back to sleep
  • Waking up too early in the morning and being unable to get back to sleep.

Exclusion Criteria:

  • Use of sedative-hypnotics, anxiolytic, or benzodiazepines within the previous 2 weeks
  • Current treatment with other sedating medications such as opioids
  • On therapy for pharmacological therapy for depression
  • History of alcohol/drug dependence
  • History of liver disease, HIV, or severe COPD
  • On Thorazine
  • Current use of ketoconazole
  • Current use of tricyclic antidepressants
  • Current use of macrolide antibiotics
  • Current use of anticonvulsant medications
  • Pregnancy. A urine pregnancy test will be performed to exclude pregnancy in potential subjects.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03307005

Layout table for location information
United States, Maryland
Johns Hopkins Bayview Campus, Asthma and Allergy Center
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
Johns Hopkins University
Layout table for investigator information
Principal Investigator: Rashmi Aurora, MD Johns Hopkins University
  Study Documents (Full-Text)

Documents provided by Johns Hopkins University:

Layout table for additonal information
Responsible Party: Johns Hopkins University Identifier: NCT03307005    
Other Study ID Numbers: IRB00142395
First Posted: October 11, 2017    Key Record Dates
Results First Posted: February 10, 2020
Last Update Posted: February 11, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Aids, Pharmaceutical
Sleep Wake Disorders
Heart Failure
Heart Diseases
Cardiovascular Diseases
Nervous System Diseases
Mental Disorders
Neurologic Manifestations
Signs and Symptoms
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action